about us -凯发一触即发

home > about us > overview| core management team | coorperation partner | contact us


usci has gathered professional and outstanding experienced elites with the ambition of promoting gene technology and innovation. from the company has created, usci has formed mature operation mode and great market distribution channel. besides, usci has advanced clinical and molecular test and gene sequencing laboratories and is equipped with the world-class gene sequencing hardware with supporting biological information analysis capacity. including nextseq 500 and hiseq 4000 high-throughput sequencing and self-developed bioinformatics analysis platform. usci is also well versed with processing large-scale samples ,and big data mining and analysis. thus, usci takes the lead in chinese gene technology research and gene product development. usci has gathered top-class international and domestic experts in genomics and clinical medicine. the core team composed of multidisciplinary talents in life sciences, clinical medicine, bioinformatics, computer science, physics and statistics can provide modern medicine health solution which integrates prevention, forecast, detection, interpretation and intervention of diseases.

currently, usci focuses on large-scale birth defect detection and tumor precision medical. by independently developing and forming a series of featured products and services, usci has successfully built all-round integration test service technology platform. our business has covered nearly 20 provinces across china. in the meantime, usci strive to improve service capability, expanded overseas and domestic business, expecting to satisfy increasing demands - for new-type clinical test services.

usci has obtained the qualification of third party clinical laboratory certified by national health and family planning commission of the prc; the approval of gene expansion laboratory; qualified unit of “2015 national tumor diagnosis and treatment high-throughput sequencing quality evaluation”. besides, usci is the high-tech enterprise in zhongguancun and scientific cooperative unit of cancer foundation of china.


usci aim to promote precision medicine mainly in oncology as well as in reproductive health. by mining big genetic data and establishing the association between genetics and clinical relevance. we hope our research can be eventually translated to a basic tool for clinical diagnosis and used to assist physician to make treatment decision. with rapid development of ngs technology, we believe that more and more people will experience using a securer, more accurate, convenient and economical clinical diagnostic test.

core management team

ye zhou, phd

phd in biomedical science program, hsc, university of new mexico. postdoctoral fellow in department of molecular pharmacology, city of hope.strong background and over 10 years of hands-on experience in molecular and cellular biology as well as translational research. expertise in next-generation sequencing, designing animal disease model, and cancer stem cells research. conceived and led the development of multiplexed transcriptome-sequencing technique and successfully applied it to identify possible prognostic biomarkers in different types of leukemia. excellent skills in combining scientific knowledge of a wide range of disciplines in novel ways to design, conduct and complete projects. exceptional abilities in data analysis, data interpretation and project presentation.

hanli xu, phd
r&d director

southeast university phd. in biomedical science.the major research direction is genetic and statistical bioinformatics. strong skills in mathematics, statistics, and data analysis.undergraduate period, built a user-friendly interface and made it commercial software to serve ag-100, the ngs platform of the lab. during the phd, developed a novel statistical method that incorporates local haplotype background to test for association between genotypes and a phenotype in baylor college of medicine. this study could help scientist reveal complex etiology of common diseases and predict the diseases in advance. have worked in china national center for food safety risk assessment for big data analysis on food and health.

scott a. ness, phd
chief science adviser

the victor and ruby hansen surface endowed professor in cancer genomics unm cancer center associate director for shared resources professor, internal medicine director, analytical and translational genomics shared resource.

jeremy jones, phd
chief science adviser

assistant professor, department of cancer biology the jones lab focuses on translational research in urologic oncology. in the setting of metastatic prostate cancer, they are developing noncompetitive androgen receptor (ar) inhibitors to control the growth of cancers resistant to ar targeted therapies. in the setting of bladder cancer, they are working to improve detection of recurrent noninvasive bladder cancer and to understand the mechanism of resistance to food and drug administration-approved fibroblast growth factor receptor-targeted drugs. in all of these urologic cancers, they are using circulating tumor cells to predict response to drug treatment and to improve patient risk stratification.

yan ning, phd
science advisor

university of new mexico phd. in biomedical sciences sr. research scientist medical oncology, university of southern california, los angeles, california efficient professional with 10+ years’ experience working on drug and assay development in preclinical and clinical trial cancer research. transcription activator-­‐like effector (tale), crisper, dna sequencing, design and develop isolation of ctc, and applied on solid tumor patients(focus on colorectal cancer, gastrointestinal cancer and ovarian cancer).identified molecular predictive and/or prognostic markers to chemotherapy in gastrointestinal cancer and ovarian cancer: focus on fluoropyrimidines, platinum compounds, and vegf inhibitors.

coorperation partner

through cooperation with cancer center of the university of new mexico and national medical center in city of hope in the united states, usci has integrated respective advantages, promoted industrialized clinical application of genomics technology in china, providing china's market with scientific cancer prevention, diagnosis and treatment clinical solutions.


the university of new mexico comprehensive cancer center is the official cancer center of new mexico and the only national cancer institute-designated cancer center in a 400-mile radius. one of the premier cancer centers nationwide, the unm ccc has 128 board-certified oncology physicians, forming new mexico’s largest cancer care team. it treats about 60 percent of adults and virtually all the children in new mexico diagnosed with cancer — more than 10,000 people— from every county in the state in more than 135,000 clinic visits each year. through its partnership with the new mexico cancer care alliance, an “exemplary national model for cancer health care delivery,” the unm ccc offers access to more than 160 clinical trials to new mexicans in every part of the state. annual research funding of more than $72 million supports the unm ccc’s 132 cancer scientists. working with partners at los alamos and sandia national laboratories, lovelace respiratory research institute, and new mexico state university, they have developed new diagnostics and drugs for leukemia, breast cancer, ovarian cancer, prostate cancer, liver and pancreatic cancer, brain cancer, and melanoma; garnered 33 new patents and 117 patents pending; and launched 13 new biotechnology companies since 2010.


city of hope is a private, not-for-profit clinical research center, hospital and graduate medical school located in duarte, california, united states. city of hope is best known as a cancer treatment center. it has been designated a comprehensive cancer center by the national cancer institute, a branch of the national institutes of health, part of the united states department of health and human services.city of hope played a role in the development of synthetic human insulin in 1978. the center has performed 12,000 hematopoietic stem cell transplants as of 2014 with patient outcomes that consistently exceed national averages.city of hope is a founding member of the national comprehensive cancer network.

contact us

add: 2f, kefang incubator, no.123, zhongguancun north st, haidian dist, beijing
tel: 010-62526182
email: service@scisoon.cn
web: www.scisoon.cn

business cooperation

tel: +86 10-62526182-819
email: partnership@scisoon.cn

human resources department

tel: +86 10-62526182-826
email: hr@scisoon.cn

customer service

tel: 4006-881-555
email: kf@scisoon.cn